Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

3D Medicines, Inc. (1244) Stock Price & Analysis

3 Followers

1244 Stock Chart & Stats

HK$2.60HK$0.02(0.78%)
At close: 4:00 PM GMT+8
HK$2HK$2.5HK$3Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 2.40 - HKD 2.60
52-Week Range
HKD 1.82 - HKD 6.07
Previous Close
HKD 2.58
Volume
N/A
Average Volume (3M)
33.18K
Market Cap
HKD 666.10M
Enterprise Value
HKD 471.71M
Total Cash (Recent Filing)
HKD 394.59M
Total Debt (Recent Filing)
HKD 171.36M
Price to Earnings (P/E)
―
Beta
0.58
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin

The very high gross margin indicates that approved products and/or the company’s commercial mix retain substantial value after direct costs. If maintained, this provides a strong base for funding development, commercialization, and eventual operating leverage as revenue stabilizes or grows.

Narrowing Losses

Meaningfully narrower losses suggest improving cost discipline, product mix, or operating execution despite the current unprofitable position. Continued improvement would extend the company’s financial runway and increase the potential for its high gross margin to translate into sustainable profitability over time.

Manageable Leverage

Moderate and declining debt-to-equity indicates the company is not currently heavily debt-funded, preserving some balance-sheet flexibility. This can support continued investment in oncology development while reducing the immediate burden of interest and refinancing obligations.

Bears Say

Revenue Contraction

A substantial revenue decline weakens operating leverage and makes it harder to absorb research, development, and commercialization costs. Unless growth resumes, the contraction could prolong losses, reduce internal funding capacity, and make the company more dependent on external capital.

Persistent Cash Burn

Ongoing negative operating and free cash flow shows that the business is consuming cash rather than funding itself. Persistent burn can constrain investment choices and increase reliance on financing, particularly if revenue remains weak or development spending stays elevated.

Sustained Unprofitability

Large operating and net losses indicate that the company has not yet demonstrated a durable path to bottom-line profitability. Continued losses can erode equity and financial resilience, limiting the ability to fund oncology programs and commercial expansion without additional capital.

3D Medicines, Inc. News

1244 FAQ

What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.82 and its highest was HK$6.07 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$666.10M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.395 earnings per share for the quarter.
Is 3D Medicines, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.395 in its last earnings report. Following the earnings report the stock price went down -4.432%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology